Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, přehledy, Research Support, U.S. Gov't, Non-P.H.S., práce podpořená grantem
PubMed
35181272
DOI
10.1016/j.trecan.2022.01.010
PII: S2405-8033(22)00017-6
Knihovny.cz E-zdroje
- Klíčová slova
- PARP inhibitors, antiangiogenic agents, bevacizumab, immunogenic cell death, platinum derivatives, taxanes,
- MeSH
- epiteliální ovariální karcinom farmakoterapie MeSH
- imunomodulace MeSH
- lidé MeSH
- nádory vaječníků * farmakoterapie MeSH
- protinádorové látky * farmakologie terapeutické užití MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Research Support, U.S. Gov't, Non-P.H.S. MeSH
- Názvy látek
- protinádorové látky * MeSH
At odds with other solid tumors, epithelial ovarian cancer (EOC) is poorly sensitive to immune checkpoint inhibitors (ICIs), largely reflecting active immunosuppression despite CD8+ T cell infiltration at baseline. Accumulating evidence indicates that both conventional chemotherapeutics and targeted anticancer agents commonly used in the clinical management of EOC not only mediate a cytostatic and cytotoxic activity against malignant cells, but also drive therapeutically relevant immunostimulatory or immunosuppressive effects. Here, we discuss such an immunomodulatory activity, with a specific focus on molecular and cellular pathways that can be harnessed to develop superior combinatorial regimens for clinical EOC care.
Department of Hematology and Oncology Hospital Universitario Morales Meseguer Murcia Spain
Department of Radiation Oncology Weill Cornell Medical College New York NY USA
Citace poskytuje Crossref.org
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
